Bicara and Merus Compete in HNSCC Drug Development RaceASCO
Bicara
MerusBicara and Merus are advancing competing therapies for head and neck cancer (HNSCC). While Merus shows strong early OS data, Bicara focuses on long-term outcomes, especially in HPV-negative patients, with a pivotal trial underway.
Sanofi Strengthens STAT6 Pipeline with NurixSanofi
NurixSanofi expands its collaboration with Nurix by licensing NX-3911, a potent STAT6 degrader targeting inflammatory diseases. The deal includes $15M upfront and up to $465M in milestones, with Nurix retaining U.S. co-development rights.
Bristol Myers Joins BioNTech in $11B Bispecific PactBMS
BioNTechBristol Myers Squibb partners with BioNTech in an $11B deal to co-develop the PD-L1xVEGF-A bispecific BNT327, strengthening its immuno-oncology portfolio amid rising competition from Merck and Pfizer.